1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

06 Mar 2024
Admin
News Article

Medigene’s iM-TCR Technology Receives Japanaese Patent

Medigene Expands Patent Portfolio in Japan for iM-TCR Technology Enhancing TCR-T Safety and Efficacy

Overview

Medigene AG has recently received a patent from the Japan Patent Office for its inducible Medigene T cell receptor (iM-TCR), a mechanism designed to regulate the efficacy and safety of its T cell receptor engineered T cell (TCR-T) therapies.

Medigene CEO on Efficacy and Safety

Selwyn Ho, CEO at Medigene, expressed satisfaction with the patent grant, noting its importance in expanding the company's intellectual property portfolio.
He emphasized the potential of the iM-TCR to provide tailored efficacy and safety for individual patients by controlling TCR activity post-administration.
Ho also highlighted the iM-TCR as an example of Medigene's End-to-End Platform, which includes various proprietary armoring and enhancement technologies.
By combining the iM-TCR with their optimal 3S (sensitive, specific, and safe) TCRs, Medigene aims to deliver innovative solutions that optimize the safety and efficacy of TCR-T therapies.

TCR-T Against Cancer

TCR-T therapies have demonstrated effectiveness in killing tumor cells, but excessive T cell activation can lead to issues such as premature exhaustion, cell death, and unwanted inflammatory responses.
The iM-TCR technology addresses these concerns by modulating TCR surface expression, enabling precise adjustment of activity against tumor cells while reducing inflammatory responses in the body.
This feature is particularly promising for sensitive organs affected by sustained inflammatory reactions caused by T cells, such as those seen in brain or liver cancer.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!